{"id":"leuprolide-acetate-la","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"10-20","effect":"Injection site reaction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"5-15","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Bone pain (initial flare)"},{"rate":"5-10","effect":"Gynecomastia"}]},"_chembl":{"chemblId":"CHEMBL1200775","moleculeType":"Protein","molecularWeight":"1269.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in castration-level testosterone suppression in males and estrogen suppression in females, making it effective for hormone-dependent conditions.","oneSentence":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:36.412Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"},{"name":"Breast cancer (premenopausal women)"}]},"trialDetails":[{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT03695237","phase":"PHASE3","title":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-24","conditions":"Central Precocious Puberty (CPP)","enrollment":45},{"nctId":"NCT03078829","phase":"","title":"The Relation of GnRH Treatment to QTc Interval in Transgender Females","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2017-05-01","conditions":"Gender Dysphoria","enrollment":3},{"nctId":"NCT02006680","phase":"","title":"Markers of Pubertal Suppression During Therapy for Precocious Puberty","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2013-12","conditions":"Central Precocious Puberty","enrollment":4},{"nctId":"NCT00380406","phase":"PHASE3","title":"PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2007-01","conditions":"Fertility Preservation, Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":194,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lupron Depot"],"phase":"phase_3","status":"active","brandName":"Leuprolide Acetate (LA)","genericName":"Leuprolide Acetate (LA)","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprolide Acetate (LA) is a medication used to treat conditions such as cancer, central precocious puberty, and prostate cancer, as well as for fertility preservation. It works by acting as a gonadotropin-releasing hormone (GnRH) agonist, which is a mechanism of action supported by ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}